Innate Pharma S.A. (IPHYF)
USD 1.45
(7.41%)
USD 1.45
(7.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -30.71 Million EUR | 26.83% |
| 2022 | -41.97 Million EUR | 29.46% |
| 2021 | -59.5 Million EUR | 49.45% |
| 2020 | -117.7 Million EUR | 36.09% |
| 2019 | -184.16 Million EUR | -24.61% |
| 2018 | -147.79 Million EUR | -58.06% |
| 2017 | -93.5 Million EUR | 45.18% |
| 2016 | -170.57 Million EUR | -14.39% |
| 2015 | -149.11 Million EUR | -148.2% |
| 2014 | -60.08 Million EUR | -79.12% |
| 2013 | -33.54 Million EUR | -28.61% |
| 2012 | -26.07 Million EUR | 21.88% |
| 2011 | -33.38 Million EUR | -33.37% |
| 2010 | -25.03 Million EUR | 35.64% |
| 2009 | -38.89 Million EUR | -257.32% |
| 2008 | -10.88 Million EUR | -338.56% |
| 2007 | -2.48 Million EUR | 12.94% |
| 2006 | -2.85 Million EUR | -42.12% |
| 2005 | -2 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -35.07 Million EUR | 1.67% |
| 2024 Q1 | -35.07 Million EUR | -14.2% |
| 2023 Q1 | -31.31 Million EUR | 25.4% |
| 2023 Q2 | -30.75 Million EUR | 1.78% |
| 2023 Q4 | -30.71 Million EUR | 1.55% |
| 2023 Q3 | -31.19 Million EUR | -1.43% |
| 2023 FY | -30.71 Million EUR | 26.83% |
| 2022 Q2 | -59.57 Million EUR | 1.38% |
| 2022 Q1 | -60.4 Million EUR | -1.52% |
| 2022 FY | -41.97 Million EUR | 29.46% |
| 2022 Q3 | -42.79 Million EUR | 28.16% |
| 2022 Q4 | -41.97 Million EUR | 1.93% |
| 2021 Q3 | -60.3 Million EUR | 31.06% |
| 2021 FY | -59.5 Million EUR | 49.45% |
| 2021 Q4 | -59.5 Million EUR | 1.33% |
| 2021 Q2 | -87.47 Million EUR | 0.95% |
| 2021 Q1 | -88.31 Million EUR | 24.97% |
| 2020 Q2 | -112.72 Million EUR | 0.66% |
| 2020 Q4 | -117.7 Million EUR | 0.66% |
| 2020 FY | -117.7 Million EUR | 36.09% |
| 2020 Q1 | -113.47 Million EUR | 38.39% |
| 2020 Q3 | -118.48 Million EUR | -5.11% |
| 2019 Q4 | -184.16 Million EUR | 0.34% |
| 2019 FY | -184.16 Million EUR | -24.61% |
| 2019 Q1 | -145.63 Million EUR | 1.46% |
| 2019 Q2 | -144.41 Million EUR | 0.83% |
| 2019 Q3 | -184.8 Million EUR | -27.96% |
| 2018 FY | -147.79 Million EUR | -58.06% |
| 2018 Q4 | -147.79 Million EUR | 0.64% |
| 2018 Q3 | -148.74 Million EUR | -100.28% |
| 2018 Q2 | -74.26 Million EUR | 1.3% |
| 2018 Q1 | -75.24 Million EUR | 19.52% |
| 2017 FY | -93.5 Million EUR | 45.18% |
| 2017 Q4 | -93.5 Million EUR | 0.97% |
| 2017 Q3 | -94.41 Million EUR | 35.48% |
| 2017 Q2 | -146.34 Million EUR | 0.61% |
| 2017 Q1 | -147.24 Million EUR | 13.68% |
| 2016 Q3 | -171.46 Million EUR | -10.08% |
| 2016 FY | -170.57 Million EUR | -14.39% |
| 2016 Q4 | -170.57 Million EUR | 0.52% |
| 2016 Q2 | -155.76 Million EUR | 0.35% |
| 2016 Q1 | -156.32 Million EUR | -4.83% |
| 2015 Q1 | -271.24 Million EUR | -351.47% |
| 2015 Q2 | -270.78 Million EUR | 0.17% |
| 2015 Q3 | -149.58 Million EUR | 44.76% |
| 2015 Q4 | -149.11 Million EUR | 0.32% |
| 2015 FY | -149.11 Million EUR | -148.2% |
| 2014 Q2 | -69.54 Million EUR | 0.63% |
| 2014 Q3 | -60.53 Million EUR | 12.96% |
| 2014 Q4 | -60.08 Million EUR | 0.75% |
| 2014 FY | -60.08 Million EUR | -79.12% |
| 2014 Q1 | -69.98 Million EUR | -108.66% |
| 2013 Q2 | -18.66 Million EUR | 2.86% |
| 2013 FY | -33.54 Million EUR | -28.61% |
| 2013 Q4 | -33.54 Million EUR | 1.42% |
| 2013 Q3 | -34.02 Million EUR | -82.3% |
| 2013 Q1 | -19.21 Million EUR | 26.33% |
| 2012 Q4 | -26.07 Million EUR | 14.73% |
| 2012 Q2 | -37.73 Million EUR | 0.0% |
| 2012 FY | -26.07 Million EUR | 21.88% |
| 2012 Q3 | -30.58 Million EUR | 18.96% |
| 2011 Q4 | -33.38 Million EUR | 0.0% |
| 2011 Q2 | -29.65 Million EUR | 0.0% |
| 2011 FY | -33.38 Million EUR | -33.37% |
| 2010 Q2 | -36.39 Million EUR | 0.0% |
| 2010 FY | -25.03 Million EUR | 35.64% |
| 2010 Q4 | -25.03 Million EUR | 0.0% |
| 2009 FY | -38.89 Million EUR | -257.32% |
| 2009 Q4 | -38.89 Million EUR | 0.0% |
| 2008 FY | -10.88 Million EUR | -338.56% |
| 2007 FY | -2.48 Million EUR | 12.94% |
| 2006 FY | -2.85 Million EUR | -42.12% |
| 2005 FY | -2 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 1717.345% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 294.836% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 7742.672% |
| SQZ Biotechnologies Company | -36.23 Million USD | 15.249% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 1469.706% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 171.769% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -387.142% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 3412.388% |
| Marizyme, Inc. | 18.56 Million USD | 265.394% |
| Genus plc | 190.6 Million USD | 116.113% |
| Pharming Group N.V. | 109.8 Million USD | 127.97% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 3670.162% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 2630.052% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 4616.471% |
| ContraFect Corporation | -6.02 Million USD | -409.658% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 2758.06% |
| IMV Inc. | 7.67 Million USD | 500.39% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 658.208% |
| ONE Bio Corp. | 9.04 Million USD | 439.733% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 337.232% |
| Mesoblast Limited | 55.85 Million USD | 154.982% |
| MultiCell Technologies, Inc. | 90.04 USD | 34109384.762% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 200.517% |
| Genscript Biotech Corporation | -1.06 Billion USD | 97.106% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 5034.733% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 3147.684% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 845.795% |
| Biomind Labs Inc. | 711.4 Thousand USD | 4417.109% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 1636.067% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 339.814% |
| Skye Bioscience, Inc. | -5.72 Million USD | -436.793% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 8637.989% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 1473.627% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 22067.898% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 22910.627% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 643.732% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 154688.01% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -4084.322% |
| EV Biologics, Inc. | 1.36 Million USD | 2345.077% |
| Q BioMed Inc. | 4.06 Million USD | 856.452% |
| GB Sciences, Inc. | 1.74 Million USD | 1857.667% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -16610.558% |
| CSL Limited | 10.52 Billion USD | 100.292% |
| Agentix Corp. | 37.63 Thousand USD | 81713.563% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 150.725% |
| Enzolytics Inc. | 981.65 Thousand USD | 3228.591% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 576.081% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -4462.844% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 1494.744% |
| argenx SE | -2.02 Billion USD | 98.486% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 170.71% |
| HST Global, Inc. | 96.79 Thousand USD | 31829.567% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 34.672% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 14993.05% |
| Halberd Corporation | 144.72 Thousand USD | 21321.523% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 534.339% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -247.424% |
| Zenith Capital Corp. | 10.06 Thousand USD | 305266.932% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 1233.864% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 1387.157% |
| AVAX Technologies, Inc. | -5.9 Million USD | -420.26% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 18768.887% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -167560.225% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 15422.903% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 1509.8% |
| Helix BioMedix, Inc. | -2.57 Million USD | -1095.005% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 251.47% |
| Kadimastem Ltd | -253.1 Thousand USD | -12034.238% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 786.76% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 15360.318% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -2344327.481% |
| LadRx Corporation | -2.03 Million USD | -1408.101% |
| Cell Source, Inc. | 9.23 Million USD | 432.67% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -150390.004% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 4935.264% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 4935.264% |
| Affymax, Inc. | -5.59 Million USD | -448.723% |
| Mobile Lads Corp. | 484.23 Thousand USD | 6442.414% |
| Itoco Inc. | 228.3 Thousand USD | 13552.18% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 22684.18% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 719.568% |
| International Stem Cell Corporation | 2.59 Million USD | 1285.792% |
| CytoDyn Inc. | 20.26 Million USD | 251.574% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -4746731.53% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -331264.624% |
| Qrons Inc. | 351.42 Thousand USD | 8839.226% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 498.546% |
| SYBLEU INC | 473.71 Thousand USD | 6583.237% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -12203.501% |
| Rebus Holdings, Inc. | 305 Thousand USD | 10169.508% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 789.07% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 49307.697% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 1508.226% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 994.351% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 459.079% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 4075.113% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -2356.96% |
| Neutra Corp. | 52.18 Thousand USD | 58949.905% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -1133.909% |
| PureTech Health plc | -167.19 Million USD | 81.631% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -12440.219% |
| IXICO plc | -4.44 Million USD | -590.998% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 332.332% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 155.992% |
| CSL Limited | 10.52 Billion USD | 100.292% |
| Cellectis S.A. | -43.81 Million USD | 29.911% |